Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733875 | 0.84 | LMNA (0.47) | LMNASMN1; SMN2GAAP2RX4BCHE | |
| SCHEMBL28186001 | 0.74 | LMNA (0.60) | LMNASMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL2757925 | 0.74 | LMNA (0.60) | LMNASMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL5255379 | 0.74 | LMNA (0.47) | LMNASMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL22653828 | 0.73 | — | — | |
| SCHEMBL3118731 | 0.73 | LMNA (0.58) | LMNASMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL8443383 | 0.71 | LMNA (0.52) | LMNASMN1; SMN2GAAP2RX4BCHE | |
| SCHEMBL12788486 | 0.71 | LMNA (0.56) | LMNASMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL13887704 | 0.71 | LMNA (0.56) | LMNASMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL25799678 | 0.70 | GRM5 (0.45) | LMNASMN1; SMN2GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3286181-B1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20190153006-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10208075-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208074-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180208613-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208612-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9982000-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3286181-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | LMNA 2091/4885SMN1; SMN2 2500/4885GAA 2438/4885 |
| US-10208074-B2 | Pyrazole compounds and method for making and using the compounds | IRAK3, IRAK1, IRAK2 | LMNA 2059/4885SMN1; SMN2 2288/4885GAA 2472/4885 |
| US-20190153006-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | LMNA 2091/4885SMN1; SMN2 2500/4885GAA 2438/4885 |
| US-20180208613-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | LMNA 2059/4885SMN1; SMN2 2288/4885GAA 2472/4885 |
| US-10208075-B2 | Pyrazole compounds and method for making and using the compounds | IRAK3, IRAK1, IRAK2 | LMNA 2059/4885SMN1; SMN2 2288/4885GAA 2472/4885 |
| US-20180208612-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | LMNA 2059/4885SMN1; SMN2 2288/4885GAA 2472/4885 |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | LMNA 2059/4885SMN1; SMN2 2288/4885GAA 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.